EPISODE · Jan 25, 2023 · 53 MIN
Episode 14. MRD in Multiple Myeloma
from Blood Cancer Talks · host Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff
1. Excellent paper on harmonization of performing and reporting MRD in multiple myeloma: https://www.nature.com/articles/s41375-020-01012-42. Does CR really matter in the era of MRD? Landmark paper from the Spanish Group: https://pubmed.ncbi.nlm.nih.gov/35560160/3. Meta-analysis showing individual-level prognostic impact of MRD on long-term outcomes in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/33284948/4. MASTER Trial-The first trial testing MRD-adapted treatment strategy in multiple myeloma : https://pubmed.ncbi.nlm.nih.gov/34898239/
What this episode covers
In this episode, we delve into MRD in myeloma with Dr. Luciano Costa and discuss the data for 3 key clinical implications: MRD as a prognostic biomarker, MRD as a tool for treatment modification, and MRD as a surrogate endpoint for drug approval.
NOW PLAYING
Episode 14. MRD in Multiple Myeloma
No transcript for this episode yet
Similar Episodes
No similar episodes found.